BOT - Anything but charting, page-8982

In terms of bringing Sofdra to market, I believe they have gone the right direction in their marketing and sales paths maximise income without the need to share revenues with externals likely at a % of total sales cost when there is already an audience struggling and begging for a solution.

For those with low level hyperhydrosis, Customer Acquisition Costs would be higher, but I don’t think they intend to chase that market initially despite it potentially being available over the long-term. A lower strength and more readily accessible options could also capture this market with more ease but it’s a lower margin game as well.

I have confidence in the board to achieve the appropriate market penetration through their initial approaches, and they’ve had six months to plan this out knowing they were only rejected for an issue that only required a simple fix (instruction changes). They’ve already been in deep discussion with relevant providers and insurers to be able to roll it out rapidly. Now we wait and see how those preparations have gone, the cost to bring to market and their margins (hopefully they’re set up to manufacture at low cost with royalty out).